Metabolic Activation and Inactivation of Irinotecan when Combined with the Human Monoclonal Antibody Bevacizumab. Journal of Analytical Oncology, [S. l.], v. 2, n. 4, p.  218–225, 2013. DOI: 10.6000/1927-7229.2013.02.04.4. Disponível em: https://neoplasiaresearch.com/index.php/jao/article/view/89. Acesso em: 29 apr. 2026.